Major milestone: Chimeric Therapeutics (ASX: CHM) commences human study for CDH17 CAR T cell therapy

May 22, 2024 02:13 PM AEST | By Aditi Sarkar

Google News:

Major milestone: Chimeric Therapeutics (ASX: CHM) commences human study for CDH17 CAR T cell therapy — Image source: Company update

Recent News

iQIYI Partners with Telkomsel to Enhance Indonesian User Experience an...

BLOG CHICKS LIFESTYLE MAGAZINE COMMENCE FEATURES ON HOME RENOVATION TR...

Skywork-Reward-V2: Leading the New Milestone for Open-Source Reward Mo...

13th World Peace Forum held in Beijing, calls for shared responsibilit...

Highlights

Chimeric has commenced the Phase 1/2 multi-centre clinical trial for its CHM CDH17 CAR T cell therapy (CHM 2101).

It is the first-in-human clinical study of CDH17 CAR T cell therapy for patients with advanced gastrointestinal (GI) cancers.

Enrolment for the trial is open at SCRI Oncology Partners in Nashville, Tennessee.

The company intends to open more clinical trial sites in 2H 2024.

Chimeric Therapeutics Limited (ASX: CHM) has announced the initiation of the Phase 1/2 multi-centre clinical trial for its CHM CDH17 CAR T cell therapy (CHM 2101). It is the first-in-human clinical study of CDH17 CAR T cell therapy for patients with advanced GI cancers.

The trial aims to determine the optimal Phase 2 dosage of CHM CDH17 (CHM 2101) while assessing its safety profile and objective response rate in individuals diagnosed with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours.

Dr. Rebecca McQualter, Chimeric’s Chief Operating Officer, ephasised that the commencement of the CHM CDH17 CAR T clinical trial signifies a significant value-creating milestone for Chimeric, showcasing the advancement of this promising asset from preclinical to clinical stages.

The Phase 1/2 trial (NCT06055439), being conducted under a US IND, is a two-stage study with enrolment now open at SCRI Oncology Partners in Nashville, Tennessee. SCRI Oncology Partners is a renowned cancer centre with expertise in executing first-in-human trials, developing new cancer medicines, and delivering complex cell and gene therapies for patients.

The company plans to establish additional clinical trial sites in 2H 2024.

The share price of CHM was AU$ 0.024, up 4.3%, at the time of drafting this article on 22 May 2024.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.